Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation - September 16, 2009-2 - Prevnar 13

System Info - 106052  SMITH, MICHAEL J  28-Sep-2009 14:16:31  SMITHM


Submission Type: Original Application   Submission ID:  125324/0    Office: OVRR  

Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

Wyeth Pharmaceuticals Inc.          

Telecon Date/Time:  16-SEP-2009 05:16 PM     Initiated by FDA?  Yes
Telephone Number:    

Communication Categorie(s):


Telecon Summary:
CBER's response to Safety Study comments contained in 9-16-2009 email (7:59 AM) from Jack Love

FDA Participants:   Julienne Vaillancourt and Marthe Bryant

Non-FDA Participants:  Love Jack, Carmel Devlin and Edwards Elizabeth

Trans-BLA Group: No

Related STNs:  None

Related PMCs:  None

Telecon Body:


From: Vaillancourt, Julienne
Sent: Wednesday, September 16, 2009 5:16 PM
To: 'Love Jack'
Cc: 'Devlin Carmel'; 'Edwards Elizabeth'; Bryant, Marthe
Subject: RE: Safety Study comments

Dear Jack,

Dr. Bryant has responded to your request for clarification on two items in her September 11, 2009, set of comments concerning the phase 4 safety study, as follows:

In response to your first question, concerning her comment 1(d):

“Grouped events” refers to ALL medically attended events and NOT just the pre-specified events. In one tabulation, the data should be presented by group of related ICD 9 codes. The choice of grouping would be the sponsor's. 

In response to your second question, concerning her comment 1(d), first bullet:

The understanding of the sponsor is correct.

Please let me know if you have any other questions.

Thank you.


From: Love Jack []
Sent: Wednesday, September 16, 2009 7:59 AM
To: Vaillancourt, Julienne
Cc: Devlin Carmel; Edwards Elizabeth
Subject: Safety Study comments

Dear Julie,

Wyeth met internally yesterday to review CBER's comments on the safety study.  They plan to meet with Kaiser tomorrow to find out if they are in agreement and can implement these requests.  The Wyeth team has two questions shown below that they were not completely certain as to what was being requested and are asking for clarification from CBER.  The Wyeth interpretation is shown next to the CBER comment.  Is there anyway you can talk this over with Marthe and get back to me today, so that the meeting with Kaiser tomorrow can address these requests appropriately? 

Item 1(d), CBER notes: "Please submit two types of tabulations: one with grouped events/ICD-9 codes..." The wyeth team understands these "grouped events" to refer to the pre-specified events previously identified by CBER.

Item 1(d), 1st bullet CBER notes: "For other doses, tabulations need not include events that occurred in the pre-vaccination control window." Wyeth interprets this to mean that the pre-vaccine window will be required for the FIRST dose only; the pre-vaccine window will NOT be utilized in all subsequent doses.


End of email

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English